Clinical Trials Logo

Immune System Diseases clinical trials

View clinical trials related to Immune System Diseases.

Filter by:

NCT ID: NCT02640014 Active, not recruiting - Clinical trials for Immune System Diseases

Oral Immunotherapy in Food Allergy in Finland

Start date: December 2015
Phase: N/A
Study type: Interventional

The outcomes of oral immunotherapy (OIT) in food allergy study will provide more knowledge of oral immunotherapy. So far the OIT has showed in clinical experiments to be a interesting way to increase the unresponsiveness in severe food allergies. However little is known about it´s long-term outcomes, immunological mechanisms and there are no previous studies about cost-utility of OIT.

NCT ID: NCT02630082 Completed - HIV Infections Clinical Trials

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

HVTN 914
Start date: April 2011
Phase: N/A
Study type: Interventional

Rectal and genital sampling in HIV prevention trials permits assessments at the site of HIV entry. Yet the safety and acceptability of circumcision and sigmoidoscopy (and associated abstinence recommendations) are unknown in uncircumcised men who have sex with men (MSM) at high risk of HIV infection. The purpose of this study is to evaluate the feasibility of methods for assessing baseline characteristics of the mucosa of MSM at risk of HIV infection in Lima, Peru.

NCT ID: NCT02594878 Recruiting - Clinical trials for Musculoskeletal Disease

Chronic Non-bacterial Osteomyelitis Treated With Pamidronate

CNOPAM
Start date: October 2015
Phase: Phase 2
Study type: Interventional

In a randomized double blind placebo controlled trial to investigate the effect of pamidronate in treatment of chronic non bacterial osteomyelitis. Main objective: 1. Reduction of the inflammatory activity in the bone lesions measured by whole body MRI after 36 weeks. 2. Healing of the inflammatory activity in the bone lesions measured by whole body MRI after 36 weeks. Secondary objectives: 1. Changes in bone lesions in whole body MRI between baseline and week 12 and between week 12 and week 36 2. Changes in bone lesions of anterior chest-wall (adults) evaluated by CT scan between baseline and week 36. 3. Changes in patient self reported outcome measures 4. Changes in inflammatory markers and bone markers.

NCT ID: NCT02579967 Recruiting - Clinical trials for Immune System Diseases

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Start date: November 19, 2015
Phase: Phase 2
Study type: Interventional

Background: Allogeneic blood or marrow transplant is when stem cells are taken from one person s blood or bone marrow and given to another person. Researchers think this may help people with immune system problems. Objective: To see if allogeneic blood or bone marrow transplant is safe and effective in treating people with primary immunodeficiencies. Eligibility: Donors: Healthy people ages 4 or older Recipients: People ages 4-75 with a primary immunodeficiency that may be treated with allogeneic blood or marrow transplant Design: Participants will be screened with medical history, physical exam, and blood tests. Participants will have urine tests, EKG, and chest x-ray. Donors will have: Bone marrow harvest: With anesthesia, marrow is taken by a needle in the hipbone. OR Blood collection: They will have several drug injections over 5-7 days. Blood is taken by IV in one arm, circulates through a machine to remove stem cells, and returned by IV in the other arm. Possible vein assessment or pre-anesthesia evaluation Recipients will have: Lung test, heart tests, radiology scans, CT scans, and dental exam Possible tissue biopsies or lumbar puncture Bone marrow and a small piece of bone removed by needle in the hipbone. Chemotherapy 1-2 weeks before transplant day Donor stem cell donation through a catheter put into a vein in the chest or neck Several-week hospital stay. They will take medications and may need blood transfusions and additional procedures. After discharge, recipients will: Remain near the clinic for about 3 months. They will have weekly visits and may require hospital readmission. Have multiple follow-up visits to the clinic in the first 6 months, and less frequently for at least 5 years.

NCT ID: NCT02535052 Active, not recruiting - Clinical trials for Chronic Kidney Disease

Investigating the Immune System in chrONIC Kidney Disease.

SONIC
Start date: July 2015
Phase: N/A
Study type: Observational

This study will investigate the function of the immune system in people with chronic kidney disease (CKD) compared to people with normal kidneys. The investigators will use standard vaccines - the seasonal flu vaccine and pneumococcal polysaccharide (Pneumovax) vaccine - to examine how the immune system responds to challenge. All subjects will receive these recommended vaccines as part of routine care. Blood and urine samples will be collected and tested at different time points to look at how the immune response develops to these vaccines and if there are any differences between people with CKD and those without. This will help us understand how CKD affects the function of the immune system.

NCT ID: NCT02527187 Completed - Clinical trials for Immune System Diseases

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

T502
Start date: September 2015
Phase: Phase 2
Study type: Interventional

The main objective is to evaluate the concentration of allergen extract of Betula verrucosa that elicit a papule equivalent to that produced by a solution of histamine dihydrochloride 10 mg / ml in size.

NCT ID: NCT02527122 Completed - Clinical trials for Immune System Diseases

Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts

MM09
Start date: July 21, 2016
Phase: N/A
Study type: Interventional

Four concentrations of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm..

NCT ID: NCT02519816 Active, not recruiting - Clinical trials for Chronic GVHD After HCT for Cancer or Immune Disease

Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD

CARE
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Phase II multicenter, Canadian only study - open to 25 subjects. Study open to subjects with steroid-refractory or dependent chronic graft vs host disease. Series of 6 aphereses and 28 re-infusions over 24 weeks. Primary endpoint is FFS at 24 weeks. Primary objective is to measure the efficacy of CARE (Continuous Alloreactive T-Cell depletion and Regulatory T-cell Expansion)

NCT ID: NCT02449746 Completed - Schizophrenia Clinical Trials

Study of Immunotherapy in Autoantibody Positive Psychosis

SINAPPS-1
Start date: August 2015
Phase: N/A
Study type: Interventional

Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them, often involving hallucinations or delusions. Psychosis and schizophrenia are common disorders which predominantly affect younger adults. Recently, the investigators discovered that 5-10% of people with psychosis have antibodies in the blood that are capable of targeting the surface of brain cells, specific to the N-methyl-D-aspartate (NMDA) receptor or voltage gated potassium channel complex, which the investigators believe may be causing the problem. Those positive for antibodies may have a problem with their immune system and this may prevent their brain from working normally. This trial aims to test the feasibility of removing or reducing the antibodies in patients' blood, using immunotherapy, and see if this improves symptoms of psychosis. Immunotherapy in this feasibility study will involve giving all patients steroid tablets and half of them will also receive a drug called "intravenous immunoglobulin" whereas the other half will have a procedure called "plasma exchange". The feasibility study is designed to identify which method of immunotherapy is most suitable for use in this patient population. Results from this will inform on the methodology used for a proposed larger randomised control trial.

NCT ID: NCT02417766 Completed - Immune Disorders Clinical Trials

NIAID Clinical Center Genomics Opportunity Protocol

Start date: June 29, 2015
Phase:
Study type: Observational

Background: - There are many types of immune disorders. These range from rare immune deficiencies to allergies to autoimmune disease like rheumatoid arthritis. Genes are the instructions our body uses to work and develop. A new technology called whole exome sequencing may help find the cause of these disorders. Whole exome sequencing is a way to look at many genes at once for errors. Researchers hope to find new gene changes that lead to immune disorders. Additionally, researchers are interested in finding the best way to manage unexpected but important findings by whole exome sequencing. Objectives: - To better understand genetic causes of immune system disorders. Also, to better understand people s thoughts and feelings about immune system disorders and new genomic testing. Eligibility: - People ages 0 100 with an immune disorder or a relative with an immune disorder. People must be at least 2 to be evaluated at the NIH clinical center. People must be at least 12 to do the survey/interview portion of the study. Design: - Participants will have their genes sequenced. They may be asked for a new sample of blood. - If participants cannot come for a study visit, they can have a blood sample collected by their local lab or doctor and sent by mail. - Researchers may or may not find the cause of the participant s immune disorder. Participants will learn that information. Some participants may be asked to return to NIH to get results and have more tests. - Researchers may share information with other studies. The data will be anonymous. - For the survey part of the study, participants will answer questions about their or their relative s immune disorder. They will also answer about their thoughts and feelings about genomic testing. - Some participants will be asked for a brief interview to ask more about the survey topics. There may be more follow-up after several months.